Drugs in MeSH Category Nicotinic Antagonists

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira Inc	ATRACURIUM BESYLATE	atracurium besylate	INJECTABLE;INJECTION	090761-001	Oct 18, 2012	AP	RX	No	No
Watson Pharms Teva	ATRACURIUM BESYLATE	atracurium besylate	INJECTABLE;INJECTION	074945-001	Jul 28, 1998		DISCN	No	No
Lgm Pharma	MECAMYLAMINE HYDROCHLORIDE	mecamylamine hydrochloride	TABLET;ORAL	204054-001	Mar 19, 2013		RX	No	Yes
Hospira Inc	ATRACURIUM BESYLATE PRESERVATIVE FREE	atracurium besylate	INJECTABLE;INJECTION	090782-001	Oct 18, 2012	AP	RX	No	No

Last updated: May 22, 2026

Market dynamics and patent landscape for Nicotinic Antagonists (MeSH)

Nicotinic antagonists (a therapeutic class spanning nicotinic acetylcholine receptor blockade) drive a patent landscape dominated by old, off-patent small molecules for respiratory neuromuscular blockade and anesthesia adjuncts, alongside more recent targeted efforts in neuropsychiatry and autonomic indications using nicotinic receptor modulation. Market dynamics are shaped by (1) longstanding generic penetration in inhaled and IV anesthesia-adjunct use, (2) supply chain concentration for sterile injectables, and (3) regulatory pathway asymmetry between small-molecule NDAs and newer fixed-dose combinations. The active patent risk sits less in “brand-new” mechanism patents and more in formulation, manufacturing, and method-of-use claims that support exclusivity extensions, product lifecycle management, and litigation settlements.

Which nicotinic antagonists matter commercially and how is the market priced?

Nicotinic antagonists in practice split into two commercial buckets:

1. Hospital anesthesia and ICU neuromuscular blockade
   Dominated by older small molecules, typically sterile injectables, where pricing is pressured by multi-source generics and procurement contracting.

2. Neuropsychiatry and autonomic symptom control
   Where development is more indication-specific and often relies on method-of-use claims and formulation IP, with smaller unit volume but higher payer and prescriber scrutiny.

What sub-classes do payers and hospitals actually buy?

• Non-depolarizing neuromuscular blockers: used for intubation and surgical paralysis in anesthesia.
• Ganglionic or autonomic nicotinic blockade agents: used less consistently across systems and geographies, often competing with alternatives (sympatholytics, alpha blockers, botulinum toxin, or device-based approaches).

What drives demand through the sales cycle?

• Procedure volume (surgery and ICU ventilator time).
• Formulary placement by GPO contracting and anesthesia services.
• Availability and sterility assurance for IV injectables.
• Switching costs are modest for generics, higher for hard-to-source sterile products.

Price pressure and margin structure

• Branded products compete primarily on availability, stability, and label specificity (duration of effect, onset time, reversal compatibility, and dosing convenience).
• Once multiple ANDA suppliers exist, price typically moves toward the lowest sustainable cost with tender-driven volatility.

What patents protect nicotinic antagonists, and where does IP actually live?

Patent estates for nicotinic antagonists concentrate in three IP buckets:

1. Active compound patents (older)
   For legacy agents, these typically expired decades ago. Current exclusivity usually comes from product-specific and process-specific claims.

2. Formulation and route-of-administration patents
   Sterile injectable formulations and specific salt forms are common targets for secondary patenting (stability, pH, buffering, osmolality, emulsions, and lyophilized reconstitution).

3. Method-of-use and dosing regimen patents
   Indication-specific claims (e.g., perioperative protocols, ICU ventilator management, or patient subpopulations) can persist even when compound IP is gone.

Common claim types seen in nicotinic antagonist life-cycle protection

• “Pharmaceutical composition comprising [salt/form] with [buffer/excipient]”
• “Method of treating [indication] by administering [dose] at [interval]”
• “Method for producing sterile drug product with [process parameters]”
• “Use of reversal agent compatibility and timing windows” (where claims tie to clinical protocol rather than a new molecule)

How long do secondary patents typically last?

Secondary patent families are often drafted to extend effective market life by anchoring to later filings of formulation and manufacturing improvements. Even when primary compound patents expired, product-specific exclusivity can carry through to the late 2020s or early 2030s depending on the product’s filing timeline and each jurisdiction’s patent term adjustments and supplementary protection frameworks.

How many patents cover nicotinic antagonists across major jurisdictions?

A full count requires drug-by-drug Orange Book and patent register aggregation. Under the MeSH “Nicotinic Antagonists” umbrella, the jurisdictional picture typically follows these patterns:

• US: patent estates include (a) Orange Book-listed patents for approved products, and (b) device-free method claims that often show up in litigation more than in Orange Book listings.
• EU: SPCs and national validation can add up to a decade of extension on certain active ingredients, but only where an SPC is granted.
• UK: similar SPC logic plus litigation dynamics around SPC validity.

Net effect: in many nicotinic antagonist sub-areas, the effective exclusivity map is driven by product-specific Orange Book listings rather than a “class” view.

When does exclusivity end for nicotinic antagonists, and what are the key expiration timelines?

For most legacy nicotinic antagonists, the key exclusivity dates already passed, and the market is governed by:

• Remaining formulation/process patent terms, if any.
• Ongoing pediatric, patent term extension, or SPCs, where granted.
• Litigation-driven “stay” periods triggered by Paragraph IV challenges.

For newer indication-specific or reformulation IP, the timeline is usually:

• Compound IP: expired or near-expired.
• Secondary patents: last extension window.
• Regulatory data exclusivity: limited role in oncology-like datasets; more often it is tied to novel indications or new combination approvals.

What Paragraph IV challenges and generic entry risks exist for nicotinic antagonist drugs?

Generic entry risk is highest where the originator’s differentiator is:

• A specific salt or formulation that is not fully protected by composition-of-matter claims, but is instead protected by secondary formulation/process patents.
• A dosing regimen or patient subpopulation method-of-use claim that creates litigation leverage but is harder to fully eliminate at ANDA/505(b)(2) stage without carving.

Typical litigation trigger points

• ANDA filers file Paragraph IV certifications asserting non-infringement or invalidity of one or more Orange Book-listed patents.
• Settlement terms often include launch date, non-designation covenants, or supply and exclusivity payments.

What stays generic launch?

• Automatic 30-month stay under Hatch-Waxman when a Paragraph IV is filed (when timely).
• Later court rulings narrowing the asserted claims still allow earlier entry if unasserted claims do not block approval.

How does the patent estate for nicotinic antagonists compare across anesthesia vs neuro indications?

Anesthesia-market nicotinic antagonists

• Patent estates are usually older.
• IP leverage is commonly in formulation and manufacturing.
• Litigation centers on sterile injectable patents and specific release profiles.

Neuro/autonomic symptom nicotinic antagonists

• Method-of-use and combination strategy are more prominent.
• Trials produce label-specific claims that can be protected by later-filed patents.
• Market-entry economics differ: fewer competitors, less tender-driven price compression, and higher payer evidence burden.

What is the Orange Book status of nicotinic antagonist drugs?

Orange Book status is product-specific. Under a MeSH class umbrella, Orange Book listings commonly show:

• Patent types: composition, method, and sometimes manufacturing.
• Multiple families: originators maintain a layered portfolio across salts, formulations, and dosage forms.
• Orange Book-driven litigation: Paragraph IV challenges track listed patents, not the broader class IP.

A class-level Orange Book summary is not actionable; the relevant competitive posture is tied to each NDA/ANDA’s listing set.

Which companies dominate the nicotinic antagonist competitive landscape?

Market power generally concentrates along three lines:

1. Originator manufacturers of legacy branded sterile injectables (now often challenged or partially genericized).
2. Large generic sterile injectables suppliers with manufacturing scale and regulatory maturity.
3. Secondary reformulation/combination entrants that win via product differentiation (stability, packaging, or dosing convenience).

Procurement-led buying patterns shift share quickly when stable multi-source supply exists.

What formulations are protected by nicotinic antagonist patents?

Formulation protection in this space typically covers:

• Salt forms and their specified stoichiometries.
• Buffers and pH ranges that stabilize active ingredients for multi-dose vials or single-dose presentation.
• Osmolality and tonicity targets to reduce injection-site risk.
• Sterilization and filtration processes aligned to shelf life and moisture sensitivity.
• Lyophilized vs liquid presentations with specified reconstitution and storage constraints.

Because nicotinic antagonists often appear as sterile injectables, manufacturing patents can be as commercially significant as formulation patents.

How does nicotinic antagonist IP affect manufacturing and regulatory approvals?

Manufacturing IP barriers impact ANDA approvals indirectly through litigation risk:

• If originator patents assert that generic manufacturing conditions change critical quality attributes tied to the protected formulation, ANDA filers face higher litigation probability.
• Even where a formulation is “generic-equivalent,” a patent claim on a narrow process window can trigger infringement contentions.

For biosimilars: not applicable unless the products are biologics. Nicotinic antagonists are generally small molecules, so the patent risk profile is mostly Hatch-Waxman driven rather than BPCIA.

What patent litigation affects nicotinic antagonist market entry?

Litigation in this sector usually involves:

• Orange Book-listed formulation and method patents.
• Disputes over equivalence of process steps.
• Settlement packages that structure market timing and non-infringement risk allocation.

Settlement agreements typically include:

• A specific launch date for the first filer or a pipeline carve-out.
• Design-around covenants limiting certain formulations or manufacturing steps.
• Mutual non-exclusivity for non-designated products.

How do settlement agreements change the generic launch scenario?

Settlement shifts the timeline in two ways:

1. It converts uncertain litigation outcomes into known entry timing for at least one generic.
2. It reduces repeat litigation for later ANDA filings via reduced risk.

As procurement moves quickly to lowest-cost reliable supply, even a small launch timing shift can change realized annual share.

What FDA regulatory status and approval pathway issues drive exclusivity?

Key factors:

• For legacy drugs, most approvals are already fully genericized.
• For reformulations/new indications, pathway use differs:
  • 505(b)(2) can allow reliance on literature and bridging studies, then opens a 3-year exclusivity window for certain new clinical investigations.
  • 505(j) ANDAs dominate for generics, where the patent and exclusivity landscape is governed by Paragraph IV strategy and Orange Book listings.

Nicotinic antagonists that are already fully generic create a market where “regulatory status” mainly affects supply continuity and labeling compliance rather than exclusivity.

Key generics entry scenarios for nicotinic antagonists

Generic launch typically follows one of three patterns:

1. Uncontested entry: patents expired; no Orange Book barriers.
2. Paragraph IV with settlement: faster entry than a fully litigated path.
3. Paragraph IV with litigation: entry delayed until courts or design-arounds clear the asserted claims.

The commercial outcome is strongly tied to:

• Sterile manufacturing capacity.
• Tender and formulary switching speed.
• Risk tolerance of GPO contracts to new entrants.

Case comparison: anesthesia neuromuscular blockade vs autonomic nicotinic antagonism

Anesthesia neuromuscular blockade (competitive dynamics)

• Fast switching once generics are available.
• Differentiation on dosing, onset, and reversal protocols rather than mechanism.
• Patent value sits in formulation and manufacturing claims.

Autonomic nicotinic antagonism (competitive dynamics)

• Label specificity drives differentiation.
• Method-of-use and dosing regimen patents can block or delay entry even when compound IP is gone.
• Smaller volumes can allow fewer competitors and longer value capture for brand owners when evidence standards are strict.

Key Takeaways

• Nicotinic antagonist market dynamics are dominated by procurement-driven pricing in hospital settings and by lifecycle IP in sterile injectable formulations.
• Patent leverage typically sits in secondary patents (formulation, process, and method-of-use), not in primary nicotinic antagonist compound claims.
• Generic entry risk hinges on Paragraph IV challenges to Orange Book-listed patents tied to product presentation and dosing protocols.
• Litigation and settlements materially shift realized launch timing; procurement cycles amplify these timing effects.
• A “MeSH class” view is insufficient for exclusivity decisions; the actionable map is product-specific Orange Book listings and the asserted patent families in each jurisdiction.

FAQs

1) Which Orange Book-listed patents most frequently drive Paragraph IV filings for nicotinic antagonists?

Typically formulation, method-of-use, and manufacturing process patents listed against the approved NDA for sterile injectable presentations.

2) Do nicotinic antagonist generics face BPCIA risk?

No. Nicotinic antagonists are generally small molecules, so the main exclusivity and litigation framework is Hatch-Waxman (505(j) and Paragraph IV), not BPCIA.

3) What claim types are easiest to design around for nicotinic antagonist formulations?

Narrowly defined excipient ratios, specific pH/buffer windows, and process-parameter claims that can be altered while maintaining Q3/Q6 comparability.

4) How does sterile injectable supply concentration affect market entry for nicotinic antagonists?

Where only a few plants are qualified, new entrants can lose share despite regulatory approval if supply reliability is weak.

5) What timeline changes occur when settlements include earlier “non-designated” carve-outs?

Carve-outs can enable certain product presentations or strengths to launch earlier than the main settlement launch date, depending on the settlement’s scope.

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA Orange Book database).
2. U.S. Food and Drug Administration. Hatch-Waxman Act framework for ANDAs, 30-month stay, and Paragraph IV certifications. (FDA guidance and statutory materials).
3. U.S. Food and Drug Administration. Drug Approval Reports and Drug Product databases. (Accessed via FDA drug approval databases).